Formycon AG
Graphique
Bon à savoir : L’investissement en actions présente un potentiel de rendement à long terme, mais implique également un risque de perte, pouvant aller jusqu’à la totalité du capital investi. Les performances passées ne préjugent pas des performances futures. Les données fournies par des sources externes n’ont pas été modifiées par Saxo. Voir la clause de non-responsabilité
À propos Formycon AG
Formycon AG is a globally operating, independent biosimilars specialist with a comprehensive product pipeline and a scalable platform for developing biosimilar drugs for various indications, including ophthalmology, immunology, and immunobiology. Its product, FYB201 (ranibizumab), is an approved biosimilar product for Lucentis, is on the market in the United States and Canada, Europe, the Middle East and North Africa (MENA), and other geographical regions. The other product candidates in its pipeline include FYB202, FYB203, FYB206, FYB207, FYB208, FYB209, and FYB210, which are biosimilar projects being developed for the treatment of various indications. Geographically, the company generates maximum revenue from Switzerland, followed by Germany.
/ 